Business
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\nData to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis\n\n VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE) resulting in potentially life-threatening damage to the kidneys, will be presented at American Society of Nephrology (ASN) Kidney Week 2021 and at American College of Rheumatology (ACR) Convergence 2021. ASN Kidney Week will take place virtually on November 2-7 and ACR Convergence will take place virtually on November 3-9.\n\n“Aurinia is committed to growing the body of clinical research supporting LUPKYNIS as a safe and effective option for people with lupus who are fighting to protect their kidneys from the destructive impact of lupus nephritis,” said Neil Solomons, M.D., Chief Medical Officer at Aurinia. “We look forward to presenting new data for LUPKYNIS at ASN and ACR, including an updated interim analysis of data from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS.”\n\nThe accepted abstract presentations and posters are listed below and can be viewed virtually from November 4-6 at ASN and from November 8-9 at ACR. The details are listed as follows.\n\nVirtual ASN Kidney Week 2021 Presentations and Posters:\n\nThursday, November 4, 2021\n\nTitle: “Chronic Dosing of Voclosporin at Clinically Relevant Exposure Levels Does Not Induce Renal Fibrosis Markers in Rats”\nPresenting author: Linda M. Rehaume, Ph.D., senior research scientist at Aurinia\nTime: Available on-demand beginning at 10:00 a.m. PDT\n\nSaturday, November 6, 2021\n\nTitle: “Voclosporin is Effective in Achieving Complete Renal Response in Severe Lupus Nephritis”\nPresenting author: Hanni Menn-Josephy, M.D., Boston Medical Center\nTime: 4:30 p.m. - 5:30 p.m. PDT\n\nVirtual ACR Convergence 2021 Presentations and Posters:\n\nMonday, November 8, 2021\n\nTitle: “Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study”\nPresenting author: Amit Saxena, M.D., NYU School of Medicine\nSession...